International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: а pragmatic guide for first-trimester screening and prevention (аdapted version in Russian edited by Z.S. Khodzhaeva, E.L. Yarotskaya, I.I. Baranov). Part 2

References

1. Tranquilli A.L., Dekker G., Magee L., et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014; 4: 97-104.

2. Magee L.A., Pels A., Helewa M., Rey E., et al.; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens 2014; 4: 105-45.

3. Lowe S.A., Bowyer L., Lust K., et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol 2015; 55: e1-29.

4. Brown M.A., Magee L.A., Kenny L.C., et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis and management recommendations for international practice. Pregnancy Hypertens 2018; 13: 291-310.

5. Villar J., Say L., Gulmezoglu A.M., Meraldi M., et al. Eclampsia and pre-eclampsia: a health problem for 2000 years. In H. Critchly, A. MacLean, L. Post, J. Walk (eds). Pre-Eclampsia. London: RCOG Press, 2003: 189-207.

6. Ronsmans C., Graham W.J. Maternal mortality: who, when, where, and why. Lancet. 2006; 368: 1189-200.

7. Kuklina E.V., Ayala C., Callaghan W.M. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol.2009; 113: 1299-306.

8. Lisonkova S., Joseph K.S. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013; 209: 544.e1-12.

9. Lisonkova S., Sabr Y., Mayer C., Young C., et al. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014; 124: 771-81.

10. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science. 2005; 308: 1592-4.

11. Jim B., Karumanchi S.A. Preeclampsia: pathogenesis, prevention, and long-term complications. Semin Nephrol. 2017; 37: 386-97.

12. Chaiworapongsa T., Chaemsaithong P., Yeo L., Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014; 10: 466-80.

13. Thilaganathan B. Pre-eclampsia and the cardiovascular-placental axis. Ultrasound Obstet Gynecol. 2018; 51: 714-7.

14. World Health Organization. WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. Geneva: WHO, 2011.

15. National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in Pregnancy: The management of Hypertensive Disorders during Pregnancy. London: RCOG Press, 2010.

16. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122: 1122-31.

17. Lowe S.A., Brown M.A., Dekker G.A., et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol. 2009; 49: 242-6.

18. Khalil A., Syngelaki A., Maiz N., Zinevich Y., et al. Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol. 2013; 42: 634-43.

19. Lamminpaa R., Vehvilainen-Julkunen K., Gissler M., Heinonen S. Preeclampsia complicated by advanced maternal age: a registry-based study on primiparous women in Finland 1997-2008. BMC Pregnancy Childb. 2012; 12: 47.

20. Yogev Y., Melamed N., Bardin R., Tenenbaum-Gavish K., et al. Pregnancy outcome at extremely advanced maternal age. Am J Obstet Gynecol. 2010; 203: 558.e1-7.

21. Balasch J., Gratacos E. Delayed childbearing: effects on fertility and the outcome of pregnancy. Curr Opin Obstet Gynecol. 2012; 24: 187-93.

22. Poon L.C.Y., Kametas N.A., Chelemen T., Leal A., et al. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens. 2010; 24: 104-10.

23. Duckitt K., Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330: 565.

24. Luo Z.-C., An N., Xu H.-R., Larante A., et al. The effects and mechanisms of primiparity on the risk of pre-eclampsia: a systematic review. Paediatr Perinat Epidemiol. 2007; 21 (suppl 1): 36-45.

25. Robillard P.Y., Hulsey T.C., Alexander G.R., Keenan A., et al. Paternity patterns and risk of preeclampsia in the last pregnancy in multiparae. J Reprod Immunol. 1993; 24: 1-12.

26. Hernandez-Diaz S., Toh S., Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ. 2009; 338: b2255.

27. Campbell D.M., MacGillivray I., Carr-Hill R. Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol. 1985; 92: 131-40.

28. Sibai B.M., el-Nazer A., Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol. 1986; 155: 1011-6.

29. Lie R.T., Rasmussen S., Brunborg H., Gjessing H.K., et al. Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ. 1998; 316: 1343-7.

30. Odegard R.A., Vatten L.J., Nilsen S.T., Salvesen K.A., et al. Risk factors and clinical manifestations of pre-eclampsia. BJOG. 2000; 107: 1410-6.

31. van Rijn B.B., Hoeks L.B., Bots M.L., Franx A., et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol. 2006; 195: 723-8.

32. Langenveld J., Jansen S., van der Post J., Wolf H., et al. Recurrence risk of a delivery before 34 weeks of pregnancy due to an early onset hypertensive disorder: a systematic review. Am J Perinatol. 2010; 27: 565-71.

33. Rousso D., Panidis D., Gkoutzioulis F., Kourtis A., et al. Effect of the interval between pregnancies on the health of mother and child. Eur J Obstet Gynecol Reprod Biol. 2002; 105: 4-6.

34. King J.C. The risk of maternal nutritional depletion and poor outcomes increases in early or closely spaced pregnancies. J Nutr.2003; 133: 1732S-6S.

35. Conde-Agudelo A., Rosas-Bermudez A., Kafury-Goeta A.C. Effects of birth spacing on maternal health: a systematic review. Am J Obstet Gynecol. 2007; 196: 297-308.

36. Mignini L.E., Carroli G., Betran A.P., et al. Interpregnancy interval and perinatal outcomes across Latin America from 1990 to 2009: a large multi-country study. BJOG. 2016; 123: 730-7.

37. Winikoff B. The effects of birth spacing on child and maternal health. Stud Fam Plann. 1983; 14: 231-45.

38. Klebanoff M.A. The interval between pregnancies and the outcome of subsequent births. N Engl J Med. 1999; 340: 643-4.

39. Jackson R.A., Gibson K.A., Wu Y.W., Croughan M.S. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. Obstet Gynecol. 2004; 103: 551-63.

40. Trogstad L., Magnus P., Moffett A., Stoltenberg C. The effect of recurrent miscarriage and infertility on the risk of pre-eclampsia. BJOG. 2009; 116: 108-13.

41. Pandey S., Shetty A., Hamilton M., Bhattacharya S., et al. Obstetric and perinatal outcomes in singleton pregnancies resulting from IVF/ICSI: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18: 485-503.

42. Thomopoulos C., Tsioufis C., Michalopoulou H., Makris T., et al. Assisted reproductive technology and pregnancy-related hypertensive complications: a systematic review. J Hum Hypertens. 2013; 27: 148-57.

43. Martin A.S., Monsour M., Kawwass J.F., Boulet S.L., et al. Risk of preeclampsia in pregnancies after assisted reproductive technology and ovarian stimulation. Matern Child Health J. 2016; 20: 2050-6.

44. Albrecht E.D., Bonagura T.W., Burleigh D.W., Enders A.C., et al. Suppression of extravillous trophoblast invasion of uterine spiral arteries by estrogen during early baboon pregnancy. Placenta. 2006; 27: 483-90.

45. Imudia A.N., Awonuga A.O., Doyle J.O., et al. Peak serum estradiol level during controlled ovarian hyperstimulation is associated with increased risk of small for gestational age and preeclampsia in singleton pregnancies after in vitro fertilization. Fertil Steril. 2012; 97: 1374-9.

46. Fisher S.J. Why is placentation abnormal in preeclampsia? Am J Obstet Gynecol. 2015; 213: S115-22.

47. Smith G.N., Walker M., Tessier J.L., Millar K.G. Increased incidence of preeclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility. Am J Obstet Gynecol. 1997; 177: 455-8.

48. Hoy J., Venn A., Halliday J., Kovacs G., et al. Perinatal and obstetric outcomes of donor insemination using cryopreserved semen in Victoria, Australia. Hum Reprod. 1999; 14: 1760-4.

49. 49 Salha O., Sharma V., Dada T., et al. The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Hum Reprod. 1999; 14: 2268-73.

50. Need J.A., Bell B., Meffin E., Jones W.R. Pre-eclampsia in pregnancies from donor inseminations. J Reprod Immunol. 1983; 5: 329-38.

51. Simeone S., Serena C., Rambaldi M.P., Marchi L., et al. Risk of preeclampsia and obstetric outcome in donor oocyte and autologous in vitro fertilization pregnancies. Minerva Ginecol. 2016; 68: 9-14.

52. Nakabayashi Y., Nakashima A., Yoshino O., et al. Impairment of the accumulation of decidual T cells, NK cells, and monocytes, and the poor vascular remodeling of spiral arteries, were observed in oocyte donation cases, regardless of the presence or absence of preeclampsia. J Reprod Immunol. 2016; 114: 65-74.

53. Arngrimsson R., Bjornsson S., Geirsson R.T., Bjornsson H., et al. Genetic and familial predisposition to eclampsia and pre-eclampsia in a defined population. Br J Obstet Gynaecol. 1990; 97: 762-9.

54. Cincotta R.B., Brennecke S.P. Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas. Int J Gynaecol Obstet. 1998; 60: 23-7.

55. Williams P.J., Broughton Pipkin F. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011; 25: 405-17.

56. Zintzaras E., Kitsios G., Harrison G.A., et al. Heterogeneity-based genome search meta-analysis for preeclampsia. Hum Genet.2006; 120: 360-70.

57. Cnattingius S., Bergstrom R., Lipworth L., Kramer M.S. Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med. 1998; 338: 147-52.

58. Weiss J.L., Malone F.D., Emig D., et al. Obesity, obstetric complications and cesarean delivery rate - a population-based screening study. Am J Obstet Gynecol. 2004; 190: 1091-7.

59. Leung T.Y., Leung T.N., Sahota D.S., et al. Trends in maternal obesity and associated risks of adverse pregnancy outcomes in a population of Chinese women. BJOG. 2008; 115: 1529-37.

60. Syngelaki A., Bredaki F.E., Vaikousi E., Maiz N., et al. Body mass index at 11-13 weeks’ gestation and pregnancy complications. Fetal Diagn Ther. 2011; 30: 250-65.

61. Liu L., Hong Z., Zhang L. Associations of prepregnancy body mass index and gestational weight gain with pregnancy outcomes in nulliparous women delivering single live babies. Sci Rep. 2015; 5: 12863.

62. Rahman M.M., Abe S.K., Kanda M., et al. Maternal body mass index and risk of birth and maternal health outcomes in low- and middle-income countries: a systematic review and meta-analysis. Obes Rev. 2015; 16: 758-70.

63. Wei Y.-M., Yang H.-X., Zhu W.-W., et al. Risk of adverse pregnancy outcomes stratified for pre-pregnancy body mass index. J Matern Fetal Neonatal Med. 2016; 29: 2205-9.

64. Catalano P.M. Obesity, insulin resistance, and pregnancy outcome. Reproduction. 2010; 140: 365-71.

65. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011; 29: 415-45.

66. Spradley F.T., Palei A.C., Granger J.P. Immune mechanisms linking obesity and preeclampsia. Biomolecules. 2015; 5: 3142-76.

67. Mittendorf R., Lain K.Y., Williams M.A., Walker C.K. Preeclampsia. A nested, case-control study of risk factors and their interactions. J Reprod Med. 1996; 41: 491-6.

68. Knuist M., Bonsel G.J., Zondervan H.A., Treffers P.E. Risk factors for preeclampsia in nulliparous women in distinct ethnic groups: a prospective cohort study. Obstet Gynecol. 1998; 92: 174-8.

69. Mostello D., Catlin T.K., Roman L., Holcomb W.L.J., et al. Preeclampsia in the parous woman: who is at risk? Am J Obstet Gynecol.2002; 187: 425-9.

70. Caughey A.B., Stotland N.E., Washington A.E., Escobar G.J. Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia. Obstet Gynecol. 2005; 106: 156-61.

71. Ghosh G., Grewal J., Mannisto T., et al. Racial/ethnic differences in pregnancy-related hypertensive disease in nulliparous women. Ethn Dis. 2014; 24: 283-9.

72. Russell R.B., Green N.S., Steiner C.A., et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics. 2007; 120: e1-9.

73. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25: 305-13.

74. Kestenbaum B., Seliger S.L., Easterling T.R., et al. Cardiovascular and thromboembolic events following hypertensive pregnancy. Am J Kidney Dis. 2003; 42: 982-9.

75. Bellamy L., Casas J.-P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007; 335: 974.

76. Khalil A., Rezende J., Akolekar R., Syngelaki A., et al. Maternal racial origin and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol. 2013; 41: 278-85.

77. Bartsch E., Medcalf K.E., Park A.L., Ray J.G. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016; 353: i1753.

78. Mudd L.M., Owe K.M., Mottola M.F., Pivarnik J.M. Health benefits of physical activity during pregnancy: an international perspective. Med Sci Sports Exerc. 2013; 45: 268-77.

79. Schneider S., Freerksen N., Rohrig S., Hoeft B., et al. Gestational diabetes and preeclampsia--similar risk factor profiles? Early Hum Dev. 2012; 88: 179-84.

80. Conti E., Zezza L., Ralli E., et al. Growth factors in preeclampsia: a vascular disease model. A failed vasodilation and angiogenic challenge from pregnancy onwards? Cytokine Growth Factor Rev. 2013; 24: 411-25.

81. de Resende Guimaraes M.F.B., Brandao AHF, de Lima Rezende C.A., et al. Assessment of endothelial function in pregnant women with preeclampsia and gestational diabetes mellitus by flow-mediated dilation of brachial artery. Arch Gynecol Obstet. 2014; 290: 441-7.

82. Kane S.C., da Silva Costa F., Brennecke S. First trimester biomarkers in the prediction of later pregnancy complications. Biomed Res Int. 2014; 2014: 807196.

83. Karacay O., Sepici-Dincel A., Karcaaltincaba D., et al. A quantitative evaluation of total antioxidant status and oxidative stress markers in preeclampsia and gestational diabetic patients in 24-36 weeks of gestation. Diabetes Res Clin Pract. 2010; 89: 231-8.

84. Wiznitzer A., Mayer A., Novack V., et al. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol. 2009; 201: 482.e1-8.

85. Zhou J., Zhao X., Wang Z., Hu Y. Combination of lipids and uric acid in mid-second trimester can be used to predict adverse pregnancy outcomes. J Matern Fetal Neonatal Med. 2012; 25: 2633-8.

86. Engeland A., Bjorge T., Daltveit A.K., et al. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway. Eur J Epidemiol. 2011; 26: 157-63.

87. Feig D.S., Shah B.R., Lipscombe L.L., et al. Preeclampsia as a risk factor for diabetes: a population-based cohort study. PLoS Med.2013; 10: e1001425.

88. Libby G., Murphy D.J., McEwan N.F., et al. Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohort. Diabetologia. 2007; 50: 523-30.

89. Mannisto T., Mendola P., Vaarasmaki M., et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. 2013; 127: 681-90.

90. Parretti E., Lapolla A., Dalfra M., et al. Preeclampsia in lean normotensive normotolerant pregnant women can be predicted by simple insulin sensitivity indexes. Hypertension. 2006; 47: 449-53.

91. Sierra-Laguado J., Garcia R.G., Celedon J., et al. Determination of insulin resistance using the homeostatic model assessment (HOMA) and its relation with the risk of developing pregnancy-induced hypertension. Am J Hypertens. 2007; 20: 437-42.

92. Legro R.S. Insulin resistance in women’s health: why it matters and how to identify it. Curr Opin Obstet Gynecol. 2009; 21: 301-5.

93. Ryan E.A., Imes S., Liu D., et al. Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes.1995; 44: 506-12.

94. D’Anna R., Baviera G., Corrado F., et al. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG. 2006; 113: 1264-9.

95. Soonthornpun K., Soonthornpun S., Wannaro P., Setasuban W., et al. Insulin resistance in women with a history of severe pre-eclampsia. J Obstet Gynaecol Res. 2009; 35: 55-9.

96. Fuh M.M.-T., Yin C.-S., Pei D., et al. Resistance to insulin-mediated glucose uptake and hyperinsulinemia in women who had preeclampsia during pregnancy. Am J Hypertens. 1995; 8: 768-71.

97. Ray J.G. Dysmetabolic syndrome, placenta-mediated disease and future risk of cardiovascular disease. Fetal Matern Med Rev.2004; 15: 231-46.

98. Harborne L., Fleming R., Lyall H., Sattar N., et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88: 4116-23.

99. Girouard J., Giguere Y., Moutquin J.-M., Forest J.-C. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension. 2007; 49: 1056-62.

100.Beck D.W., Menezes A.H. Intracerebral hemorrhage in a patient with eclampsia. JAMA. 1981; 246: 1442-3.

101.Zhang J., Meikle S., Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy. 2003; 22: 203-12.

102.Chesley L.C., Annitto J.E., Cosgrove R.A. The remote prognosis of eclamptic women. Sixth periodic report. Am J Obstet Gynecol.1976; 124: 446-59.

103.Kaaja R. Insulin resistance syndrome in preeclampsia. Semin Reprod Endocrinol 1998; 16: 41-6.

104.Garovic V.D., Hayman S.R. Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol.2007; 3: 613-22.

105.Craici I., Wagner S., Garovic V.D. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis. 2008; 2: 249-59.

106.Brown M.C., Best K.E., Pearce M.S., Waugh J., et al. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013; 28: 1-19.

107.McDonald S.D., Malinowski A., Zhou Q., Yusuf S., et al. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008; 156: 918-30.

108.McDonald S.D., Han Z., Walsh M.W., Gerstein H.C., et al. Kidney disease after preeclampsia: a systematic review and meta-analysis. Am J Kidney Dis. 2010; 55: 1026-39.

109.Fisher K.A., Luger A., Spargo B.H., Lindheimer M.D. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore). 1981; 60: 267-76.

110.Vikse B.E., Irgens L.M., Leivestad T., Skjaerven R., et al. Preeclampsia and the risk of end-stage renal disease. N Engl J Med.2008; 359: 800-9.

111.Callaway L.K., Lawlor D.A., O’Callaghan M., Williams G.M., et al. Diabetes mellitus in the 21 years after a pregnancy that was complicated by hypertension: findings from a prospective cohort study. Am J Obstet Gynecol. 2007; 197: 492.e1-7.

112.Carr D.B., Newton K.M., Utzschneider K.M., et al. Preeclampsia and risk of developing subsequent diabetes. Hypertens Pregnancy.2009; 28: 435-47.

113.Carty D.M., Delles C., Dominiczak A.F. Preeclampsia and future maternal health. J Hypertens. 2010; 28: 1349-55.

114.Yu C.K.H., Khouri O., Onwudiwe N., Spiliopoulos Y., et al. Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol. 2008; 31: 310-3.

115.Teramo K.A., Hiilesmaa V.K., Schwartz R., Clemons G.K., et al. Amniotic fluid and cord plasma erythropoietin levels in pregnancies complicated by preeclampsia, pregnancy-induced hypertension and chronic hypertension. J Perinat Med. 2004; 32: 240-7.

116.Aali B.S., Malekpour R., Sedig F., Safa A. Comparison of maternal and cord blood nucleated red blood cell count between pre-eclamptic and healthy women. J Obstet Gynaecol Res. 2007; 33: 274-8.

117.Yucesoy G., Ozkan S., Bodur H., et al. Maternal and perinatal outcome in pregnancies complicated with hypertensive disorder of pregnancy: a seven year experience of a tertiary care center. Arch Gynecol Obstet. 2005; 273: 43-9.

118.Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009; 33: 130-7.

119.Yerlikaya G., Akolekar R., McPherson K., Syngelaki A., et al. Prediction of stillbirth from maternal demographic and pregnancy characteristics. Ultrasound Obstet Gynecol. 2016; 48: 607-12.

120.Moutquin J.-M. Classification and heterogeneity of preterm birth. BJOG. 2003; 110 (suppl): 30-3.

121.Ilekis J.V., Reddy U.M., Roberts J.M. Preeclampsia - a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod Sci. 2007; 14: 508-23.

122.Marlow N., Wolke D., Bracewell M.A., Samara M. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med. 2005; 352: 9-19.

123.Khashu M., Narayanan M., Bhargava S., Osiovich H. Perinatal outcomes associated with preterm birth at 33 to 36 weeks’ gestation: a population-based cohort study. Pediatrics. 2009; 123: 109-13.

124.Osmond C., Barker D.J. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. Environ Health Perspect. 2000; 108 (suppl): 545-53.

125.Bibbins-Domingo K., Grossman D.C., Curry S.J., et al. Screening for preeclampsia: US Preventive Services Task Force Recommendation Statement. JAMA. 2017; 317: 1661-7.

126.Committee Opinion No. 638. First-trimester risk assessment for early-onset preeclampsia. Obstet Gynecol. 2015; 126: e25-7.

127.ACOG Committee Opinion No. 743 Summary. Low-dose aspirin use during pregnancy. Obstet Gynecol 2018; 132: 254-6.

128.LeFevre M.L. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 161: 819-26.

129.Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes - 2018. Diabetes Care. 2018; 41: S137-43.

130.Wallenburg H.C. Prevention of pre-eclampsia: status and perspectives 2000. Eur J Obstet Gynecol Reprod Biol. 2001; 94: 13-22.

131.O’Gorman N., Wright D., Poon L.C., et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017; 49: 756-60.

132.Akolekar R., Syngelaki A., Poon L., Wright D., et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013; 33: 8-15.

133.O’Gorman N., Wright D., Syngelaki A., et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016; 214: 103.e1-12.

134.O’Gorman N., Wright D., Poon L.C., et al. Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet Gynecol. 2017; 49: 751-5.

135.Rolnik D.L., Wright D., Poon L.C.Y., et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017; 50: 492-5.

136.Tan M.Y., Wright D., Syngelaki A., et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018; 51: 743-50.

137.Tan M.Y., Syngelaki A., Poon L.C., et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet Gynecol. 2018; 52: 186-95.

138.Poon L.C., Rolnik D.L., Tan M.Y., et al. ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. Ultrasound Obstet Gynecol. 2018; 51: 738-42.

139.Park F.J., Leung C.H.Y., Poon L.C.Y., Williams P.F., et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Aust N Z J Obstet Gynaecol. 2013; 53: 532-9.

140.Oliveira N., Magder L.S., Blitzer M.G., Baschat A.A. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol. 2014; 44: 279-85.

141.Lobo G.A.R., Nowak P.M., Panigassi A.P., et al. Validation of Fetal Medicine Foundation algorithm for prediction of pre-eclampsia in the first trimester in an unselected Brazilian population. J Matern Fetal Neonatal Med. 2019; 32: 286-92.

142.Rocha R.S., Alves J.A.G., Maia e Holanda Moura S.B., et al. Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy. J Perinat Med. 2017; 45: 843-9.

143.Wright D., Syngelaki A., Akolekar R., Poon L.C., et al. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol. 2015; 213: 62.e1-10.

144.Poon L.C.Y., Zymeri N.A., Zamprakou A., Syngelaki A., et al. Protocol for measurement of mean arterial pressure at 11-13 weeks’ gestation. Fetal Diagn Ther. 2012; 31: 42-8.

145.Wright A., Wright D., Ispas C.A., Poon L.C., et al. Mean arterial pressure in the three trimesters of pregnancy: effects of maternalcharacteristics and medical history. Ultrasound Obstet Gynecol. 2015; 45: 698-706.

146.Poon L.C.Y., Kametas N.A., Pandeva I., Valencia C., et al. Mean arterial pressure at 11(+0) to 13(+6) weeks in the prediction of preeclampsia. Hypertension. 2008; 51: 1027-33.

147.National Heart Foundation of Australia. Hypertension Management Guide for Doctors. 2004. URL: www.heartfoundation.org.au.

148.Poon L.C.Y., Kametas N.A., Valencia C., Chelemen T., et al. Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11-13 weeks. Hypertens Pregnancy. 2011; 30: 93-107.

149.Poon L.C.Y., Kametas N., Strobl I., Pachoumi C., et al. Inter-arm blood pressure differences in pregnant women. BJOG. 2008; 115: 1122-30.

150.Maynard S.E., Min J.-Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111: 649-58.

151.Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350: 672-83.

152.Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004; 95: 884-91.

153.Chau K., Hennessy A., Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens. 2017; 31: 782-6.

154.Wortelboer E.J., Koster M.P.H., Kuc S., et al. Longitudinal trends in fetoplacental biochemical markers, uterine artery pulsatility index and maternal blood pressure during the first trimester of pregnancy. Ultrasound Obstet Gynecol. 2011; 38: 383-8.

155.Tidwell S.C., Ho H.N., Chiu W.H., Torry R.J., et al. Low maternal serum levels of placenta growth factor as an antecedent of clinicalpreeclampsia. Am J Obstet Gynecol. 2001; 184: 1267-72.

156.Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004; 89: 770-5.

157.Akolekar R., Zaragoza E., Poon L.C.Y., Pepes S., et al. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008; 32: 732-9.

158.Zhong Y., Zhu F., Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. BMC Pregnancy Childb. 2015; 15: 191.

159.Smith G.C.S., Stenhouse E.J., Crossley J.A., Aitken D.A., et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002; 87: 1762-7.

160.Spencer K., Yu C.K.H., Cowans N.J., Otigbah C., et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005; 25: 949-53.

161.Dugoff L., Hobbins J.C., Malone F.D., et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004; 191: 1446-51.

162.162 Morris R.K., Bilagi A., Devani P., Kilby M.D. Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. Prenat Diagn. 2017; 37: 253-65.

163.Wright D., Silva M., Papadopoulos S., Wright A., et al. Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015; 46: 42-50.

164.Sotiriadis A., Hernandez-Andrade E., da Silva Costa F., et al. ISUOG Practice Guidelines: role of ultrasound in screening for and follow-up of pre-eclampsia. Ultrasound Obstet Gynecol 2019. Vol. 53, N 1. P. 7-22. doi: 10.1002/uog.20105.

165.Carbillon L., Perrot N., Uzan M., Uzan S. Doppler ultrasonography and implantation: a critical review. Fetal Diagn Ther. 2001; 16: 327-32.

166.Carbillon L., Challier J.C., Alouini S., Uzan M., et al. Uteroplacental circulation development: Doppler assessment and clinical importance. Placenta. 2001; 22: 795-9.

167.Olofsson P., Laurini R.N., Marsal K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol. 1993; 49: 161-8.

168.Lefebvre J., Demers S., Bujold E., et al. Comparison of two different sites of measurement for transabdominal uterine artery Doppler velocimetry at 11-13 weeks. Ultrasound Obstet Gynecol. 2012; 40: 288-92.

169.Velauthar L., Plana M.N., Kalidindi M., et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women. Ultrasound Obstet Gynecol. 2014; 43: 500-7.

170.Magee L.A., Dadelszen P.V., Stones W.M.M. The FIGO Textbook of Pregnancy Hypertension. An evidence-based guide to monitering, prevention and management. London: The Global Library of Woman’s Medicine, 2016.

171.Nicholaides K.H., Poon C.Y.L., Fonseca E.B., the FIGO Working Group on the Best Practice in Maternal Fetal Medicine. First trimester screening and prevention of preeclampsia in singleton pregnancy. Int J Gynaecol Obstet.

172.

172. Al-Rubaie Z., Askie L.M., Ray J.G., Hudson H.M., et al. The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: a systematic review. BJOG. 2016; 123: 1441-52.

173. Wright D., Gallo D.M., Gil Pugliese S., Casanova C., et al. Contingent screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2016; 47: 554-9.

174. Francisco C., Wright D., Benko Z., Syngelaki A., et al. Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet Gynecol. 2017; 50: 589-95.

175. Sibai B.M. Thrombophilia and severe preeclampsia: time to screen and treat in future pregnancies? Hypertension. 2005; 46: 1252-3.

176. Dekker G., Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet. 2001; 357: 209-15.

177. Crandon A.J., Isherwood D.M. Effect of aspirin on incidence of pre-eclampsia. Lancet. 1979; 1: 1356.

178. Beaufils M., Uzan S., Donsimoni R., Colau J.C. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet. 1985; 1: 840-2.

179. Askie LM, Duley L., Henderson-Smart D.J., Stewart L.A. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007; 369: 1791-8.

180. Bujold E., Roberge S., Nicolaides K.H. Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation. Prenat Diagn. 2014; 34: 642-8.

181. Roberge S., Giguere Y., Villa P., et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2012; 29: 551-6.

182. Rolnik D.L., Wright D., Poon L.C., et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017; 377: 613-22.

183. Wright D., Rolnik D.L., Syngelaki A., et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. Am J Obstet Gynecol. 2018; 218: 612.e1-6.

184. Ayala D.E., Ucieda R., Hermida R.C. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013; 30: 260-79.

185. Roberge S., Bujold E., Nicolaides K.H. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2018; 218: 287-93.e1.

186. Masotti G., Galanti G., Poggesi L., Abbate R., et al. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet. 1979; 2: 1213-7.

187. Wright D., Poon L.C., Rolnik D.L., et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: Influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol. 2017; 217: 685.e1-5.

188. Henderson J.T., Whitlock E.P., O’Conner E., Senger C.A., et al. Low-dose aspirin for the prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160 (10): 695-703.

189. Duley L., Henderson-Smart D.J., Meher S., King J.F. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; 2: CD004659.

190. Roberge S., Bujold E., Nicolaides K.H. Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. Am J Obstet Gynecol. 2018; 218: 483-9.

191. Hofmeyr G.J., Lawrie T.A., Atallah A.N., Torloni M.R. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2018; 10: CD001059.

192. Rodger M.A., Gris J.-C., de Vries J.I.P., et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016; 388: 2629-41.

193. Mastrolia S.A., Novack L., Thachil J., et al. LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis. Thromb Haemost. 2016; 116: 868-78.

194. Chiswick C., Reynolds R.M., Denison F., et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015; 3: 778-86.

195. Kalafat E., Sukur Y.E., Abdi A., Thilaganathan B., et al. Metformin for the prevention of hypertensive disorders of pregnancy in women with gestational diabetes and obesity: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018. Vol. 52, N 6. P. 706-14. doi: 10.1002/uog.19084.

196. Rumbold A., Ota E., Nagata C., Shahrook S., et al. Vitamin C supplementation in pregnancy. Cochrane database Syst Rev. 2015; 9: CD004072.

197. Rumbold A., Ota E., Hori H., Miyazaki C., et al. Vitamin E supplementation in pregnancy. Cochrane Database Syst Rev. 2015; 9: CD004069. doi: 10.1002/14651858.CD004069.pub3.

198. Wen S.W., White R.R., Rybak N., et al. Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. BMJ. 2018; 362: k3478.

199. Bergeron T.S., Roberge S., Carpentier C., Sibai B., et al. Prevention of preeclampsia with aspirin in multiple gestations: a systematic review and meta-analysis. Am J Perinatol. 2016; 33: 605-10.

200. Say L., Chou D., Gemmill A., et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014; 2: e323-33.

201. Moller A.-B., Petzold M., Chou D., Say L. Early antenatal care visit: a systematic analysis of regional and global levels and trends of coverage from 1990 to 2013. Lancet Glob Health. 2017; 5: e977-83.

202. Phillips E., Stoltzfus R.J., Michaud L., Pierre G.L.F., et al. Do mobile clinics provide high-quality antenatal care? A comparison of care delivery, knowledge outcomes and perception of quality of care between fixed and mobile clinics in central Haiti. BMC Pregnancy Childb. 2017; 17: 361.

203. Ortved D., Hawkins T.L.-A., Johnson J.-A., Hyett J., et al. The cost-effectiveness of first trimester screening and early preventative use of aspirin in women at high risk of early onset pre-eclampsia. Ultrasound Obstet Gynecol. 2019; 53 (2): 239-44. doi:10.1002/uog.19076.

204. McLaren Z.M., Sharp A., Hessburg J.P., et al. Cost effectiveness of medical devices to diagnose pre-eclampsia in low-resource settings. Dev Eng. 2017; 2: 99-106.

205. Pourat N., Martinez A.E., Jones, J.M., Gregory K.D., et al. Costs of Gestational Hypertensive Disorders in California: Hypertension, Preeclampsia, and Eclampsia. Los Angeles, CA: UCLA Center for Health Policy Research, 2013.

206. Fox A., McHugh S., Browne J., Kenny L.C., et al. Estimating the cost of preeclampsia in the healthcare system: cross-sectional study using data from SCOPE study (screening for pregnancy end points). Hypertension. 2017; 70: 1243-9.

207. Phibbs C.S., Schmitt S.K., Cooper M., Gould J.B., et al. Birth hospitalization costs and days of care for mothers and neonates in California, 2009-2011. J Pediatr. 2018 Oct 5. pii: S0022-3476(18)31215-0.

208. Stevens W., Shih T., Incerti D., et al. Short-term costs of preeclampsia to the United States health care system. Am J Obstet Gynecol. 2017; 217: 237-48.e16.

209. Shmueli A., Meiri H., Gonen R. Economic assessment of screening for pre-eclampsia. Prenat Diagn. 2012; 32: 29-38.

210. Werner E.F., Hauspurg A.K., Rouse D.J. A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet Gynecol. 2015; 126: 1242-50.

211. Helou A., Walker S., Stewart K., George J. Management of pregnancies complicated by hypertensive disorders of pregnancy: could we do better? Aust N Z J Obstet Gynaecol. 2017; 57: 253-9.

212. Petersen T.G., Liew Z., Andersen A.N., Andersen G.L., et al. Use of paracetamol, ibuprofen or aspirin in pregnancy and risk of cerebral palsy in the child. Int J Epidemiol. 2018; 47: 121-30.

213. Meertens L.J.E., Scheepers H.C.J., Willemse J.P.M.M., Spaanderman M.E.A., et al. Should women be advised to use calcium supplements during pregnancy? A decision analysis. Matern Child Nutr. 2018; 14 (1). doi: 10.1111/mcn.12479. Epub 2017 Jun 18.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)